These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1411 related items for PubMed ID: 35468322

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
    Ludvik B, Giorgino F, Jódar E, Frias JP, Fernández Landó L, Brown K, Bray R, Rodríguez Á.
    Lancet; 2021 Aug 14; 398(10300):583-598. PubMed ID: 34370970
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP, Nauck MA, Van J, Kutner ME, Cui X, Benson C, Urva S, Gimeno RE, Milicevic Z, Robins D, Haupt A.
    Lancet; 2018 Nov 17; 392(10160):2180-2193. PubMed ID: 30293770
    [Abstract] [Full Text] [Related]

  • 4. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.
    Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T.
    Lancet; 2023 Aug 12; 402(10401):529-544. PubMed ID: 37385280
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
    Mosenzon O, Blicher TM, Rosenlund S, Eriksson JW, Heller S, Hels OH, Pratley R, Sathyapalan T, Desouza C, PIONEER 5 Investigators.
    Lancet Diabetes Endocrinol; 2019 Jul 12; 7(7):515-527. PubMed ID: 31189517
    [Abstract] [Full Text] [Related]

  • 6. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
    Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K, SURPASS-2 Investigators.
    N Engl J Med; 2021 Aug 05; 385(6):503-515. PubMed ID: 34170647
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.
    Inagaki N, Takeuchi M, Oura T, Imaoka T, Seino Y.
    Lancet Diabetes Endocrinol; 2022 Sep 05; 10(9):623-633. PubMed ID: 35914543
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
    Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, Mao H, Cui X, Karanikas CA, Thieu VT.
    Lancet; 2021 Jul 10; 398(10295):143-155. PubMed ID: 34186022
    [Abstract] [Full Text] [Related]

  • 9. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
    Pratley R, Amod A, Hoff ST, Kadowaki T, Lingvay I, Nauck M, Pedersen KB, Saugstrup T, Meier JJ, PIONEER 4 investigators.
    Lancet; 2019 Jul 06; 394(10192):39-50. PubMed ID: 31186120
    [Abstract] [Full Text] [Related]

  • 10. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
    Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, Mao H, Zhang S, Ahmad NN, Bunck MC, Benabbad I, Zhang XM, SURMOUNT-2 investigators.
    Lancet; 2023 Aug 19; 402(10402):613-626. PubMed ID: 37385275
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
    Dejgaard TF, Frandsen CS, Hansen TS, Almdal T, Urhammer S, Pedersen-Bjergaard U, Jensen T, Jensen AK, Holst JJ, Tarnow L, Knop FK, Madsbad S, Andersen HU.
    Lancet Diabetes Endocrinol; 2016 Mar 19; 4(3):221-232. PubMed ID: 26656289
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, Chow F.
    Lancet Diabetes Endocrinol; 2017 May 19; 5(5):341-354. PubMed ID: 28385659
    [Abstract] [Full Text] [Related]

  • 14. Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
    Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, Bekiari E.
    Diabetologia; 2022 Aug 19; 65(8):1251-1261. PubMed ID: 35579691
    [Abstract] [Full Text] [Related]

  • 15. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
    Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ, SURPASS-4 Investigators.
    Lancet; 2021 Nov 13; 398(10313):1811-1824. PubMed ID: 34672967
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
    Battelino T, Bergenstal RM, Rodríguez A, Fernández Landó L, Bray R, Tong Z, Brown K.
    Lancet Diabetes Endocrinol; 2022 Jun 13; 10(6):407-417. PubMed ID: 35468321
    [Abstract] [Full Text] [Related]

  • 17. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
    Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Rodríguez Á.
    Lancet Diabetes Endocrinol; 2022 Jun 13; 10(6):393-406. PubMed ID: 35468325
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
    Frias JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, Macura S, Mathieu C, Pedersen SD, Davies M.
    Lancet; 2023 Aug 26; 402(10403):720-730. PubMed ID: 37364590
    [Abstract] [Full Text] [Related]

  • 19. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
    Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S, Haupt A, Benson CT, Hernandez-Illas M, D'Alessio DA, Milicevic Z.
    Lancet; 2022 Nov 26; 400(10366):1869-1881. PubMed ID: 36354040
    [Abstract] [Full Text] [Related]

  • 20. Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial.
    Kadowaki T, Chin R, Ozeki A, Imaoka T, Ogawa Y.
    Lancet Diabetes Endocrinol; 2022 Sep 26; 10(9):634-644. PubMed ID: 35914542
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 71.